Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 2/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23610091 | 1.00 | HDAC6 (0.32) | HDAC6HDAC1HDAC2NOS1NOS3 | |
| SCHEMBL30759373 | 0.90 | HDAC1 (0.33) | HDAC6HDAC1HDAC2 | |
| SCHEMBL30759361 | 0.85 | AAK1 (0.37) | HDAC6HDAC1HDAC2 | |
| SCHEMBL17369159 | 0.84 | CA1 (0.37) | HDAC6HDAC1HDAC2NOS1NOS3 | |
| SCHEMBL23610157 | 0.84 | HDAC6 (0.36) | HDAC6HDAC1HDAC2NOS1NOS3 | |
| SCHEMBL16379305 | 0.84 | CA1 (0.37) | HDAC6HDAC1HDAC2NOS1NOS3 | |
| SCHEMBL21301754 | 0.82 | NOS1 (0.31) | NOS1NOS3NOS2 | |
| SCHEMBL17614514 | 0.81 | HDAC1 (0.31) | HDAC6HDAC1HDAC2 | |
| SCHEMBL17614515 | 0.81 | CA2 (0.40) | HDAC6HDAC1HDAC2 | |
| SCHEMBL21685040 | 0.81 | TDP1 (0.37) | HDAC6HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11518779-B2 | Inhibitors of DNMT1 as anticancer therapeutic agents | VICTORIA LINK LIMITED (NZ) | 2022-12-06 | — | — | US | disclosed |
| US-20210206795-A1 | INHIBITORS OF DNMT1 AS ANTICANCER THERAPEUTIC AGENTS | VICTORIA LINK LTD (NZ) | 2021-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11518779-B2 | Inhibitors of DNMT1 as anticancer therapeutic agents | DNMT1, DNMT3A, DNMT3B | HDAC6 215/4885HDAC1 33/4885HDAC2 135/4885 |
| US-20210206795-A1 | INHIBITORS OF DNMT1 AS ANTICANCER THERAPEUTIC AGENTS | DNMT1, DNMT3B, DNMT3A | HDAC6 116/4885HDAC1 18/4885HDAC2 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.